A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a dose escalating cohort study to determine the maximum tolerated dose (MTD) of
KW-2871 (in dose cohorts of 60, 80, and 100 mg/m2) when administered with a specified
premedication regimen (ranitidine, diphenhydramine, and dexamethasone). KW-2871 will be
administered at 14-day intervals.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.